Candel therapeutics announces it expects to report topline data from its phase 2 clinical trial of can-2409 in non-small cell lung cancer in the second quarter of 2024

Needham, mass., june 13, 2023 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that, in the second quarter of 2024, it expects to report topline overall survival data from its ongoing, open-label, phase 2 clinical trial of can-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor treatment (ici) in patients with non-resectable, stage iii/iv non-small cell lung cancer (nsclc) who progressed while on treatment with pd-(l)1 inhibitor therapy (cohort 2).
CADL Ratings Summary
CADL Quant Ranking